Search clinical trials for: Non-interventional (NIS)

Total 1256 results

AstraZeneca

Completed

IBIS: Italian Burden of Illness on Schizophrenia & Bipolar Disorder (IBIS)

Schizophrenia | Bipolar Disorder

Italy
AstraZeneca

Completed

Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma (MUTACT)

Non Small Cell Lung Cancer

France
AstraZeneca

Completed

Study Evaluating Management of Patients With Community-Acquired Pneumonia (CAP) or Complicated Skin Infections (REACH)

Community Acquired Pneumonia (CAP) | Complicated Skin and Skin Structures Infections (cSSSI)

France, Italy, Spain, United Kingdom, Germany, Netherlands, Belgium, Portugal, Greece, Turkey
AstraZeneca

Completed

An Observational Study Evaluating Cholesterol Levels in Patients on Cholesterol Lowering Drugs in Jordan and Lebanon (CEPHEUS)

High Blood Cholesterol
AstraZeneca

Completed

Breast Cancer Tumor Care Observational Programme

Arthralgia | Post Menopausal

Austria
AstraZeneca

Completed

Observational Study to Evaluate Health Status of Chronic Obstructive Pulmonary Disease (COPD) Patients in Response to Real-life Treatments in Thailand

Chronic Obstructive Pulmonary Disease

Thailand
AstraZeneca

Completed

Assessment of NSAID-treated Patients Adherence to Co-prescribed Proton Pump Inhibitor (PPI) (CONVOY)

Osteoarthritis | Rheumatoid Arthritis | Ankylosing Spondylitis

Sweden
AstraZeneca

Completed

Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia (CEPHEUS)

Hypercholesterolemia
AstraZeneca

Completed

A Retrospective Study of Cardiovascular Events Related to the Use of Glucose Lowering Drug Treatment in Primary Care (ROSE)

Diabetes Type II

Sweden
AstraZeneca

Completed

Symptom Control and Impact on Daily Life in Patients With Gastroesophageal Reflux Disease

Gastroesophageal Reflux Disease

Bulgaria
AstraZeneca

Completed

The Study to Describe Symptom Control and Impact on Daily Life in Gastroesophageal Reflux Disease (GERD) Patients

Gastroesophageal Reflux Disease

Bosnia and Herzegovina
AstraZeneca

Completed

Polish Survey on the Efficacy of the Hypercholesterolemia Treatment (CEPHEUS)

Hypercholesterolemia
AstraZeneca

Completed

A Non Interventional Study to Investigating the Ratio of Mis-diagnosed Bipolar Symptoms in Patient With Major Depressive Disorder (MDD) (Improve)

Major Depressive Disorder | MDD

Italy
AstraZeneca

Completed

A Study for the Assessment of the Words Used by Patients and Physicians to Express the Symptoms of Chronic Obstructive Pulmonary Disease (COPD) (COPD Language)

Chronic Obstructive Pulmonary Disease

Greece
AstraZeneca

Completed

CARE - Quality Improvement in Cardiovascular Secondary Prevention in Primary Care, Through Delegation of Consultations to the Nurse.

Cardiovascular Disease

Denmark
AstraZeneca

Completed

Symbicort Usage in Asthma Treatment and Impact of a New Therapeutic Strategy on Compliance and Asthma Control in France (SYMBIOSE)

Asthma

France
AstraZeneca
Hellenic Cardiovascular Research Society

Completed

An Epidemiological Study of Acute Coronary Syndromes in The Greek Population. The TARGET Study (TARGET)

Acute Coronary Syndromes

Greece
AstraZeneca

Completed

Survey of Lipid Goal Attainment and Mortality in Patients With High Cardiovascular Risk in Thailand

Dyslipidemia

Thailand
AstraZeneca

Completed

Study of Incidence of Drug-induced Upper Gastrointestinal Bleeding

Upper Gastrointestinal Bleeding

Russian Federation
AstraZeneca

Completed

Observational Study to Evaluate Bipolar Disorder Symptoms in Patients Presented With Schizophrenia or Depression

Schizophrenia | Schizoaffective Disorder | Recurrent Depression

Russian Federation
AstraZeneca

Completed

Seroquel XR in the Long Term Treatment of Schizophrenia (SereNIS)

Relapse in Schizophrenia

Hungary
AstraZeneca

Completed

Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)

Non-Small Cell Lung Cancer

Netherlands
AstraZeneca

Completed

Estimating the Use of Resources and the Costs of Treating Patients With Asthma in the Autonomous Community of Valencia

Asthma | Valencia Autonomous Region

Spain
AstraZeneca

Completed

Secondary Prevention Treatment in Patients Who Have Suffered a Cardiovascular Event

Cardiovascular Events
AstraZeneca

Completed

Impact of Morning Symptoms in Clinical Control of Chronic Obstructive Pulmonary Disease (COPD) (IMPAEPOC)

COPD

Spain
AstraZeneca

Completed

Utilization of Fixed Combination (Budesonide/Formoterol and Salmeterol/Fluticasone and Beclomethasone/Formoterol) in Treatment of Asthma Patients (UFO)

Asthma

Czech Republic
AstraZeneca

Completed

Education and Awareness Program Targeting the Assessment of Adherence of the Treatment of Dyslipidemia (PRECAVER)

Patients With Dyslipidemia

Brazil
AstraZeneca

Completed

Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Track (GIT) Symptoms in Thailand (GerdQ)

Upper GIT Symptoms

Thailand
AstraZeneca

Completed

European Study to Describe Hospital Stay in Patients Admitted for Acute Bipolar Manic Episodes

Acute Bipolar Manic Episode

Croatia, Italy, Turkey, United Kingdom, Germany, Belgium, Finland, Denmark
AstraZeneca

Completed

Evaluation of Symbicort® Turbuhaler® (Budesonide/Formoterol) in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease
AstraZeneca

Completed

Cost-effectiveness Study of Symbicort as Maintenance and Reliever Therapy (SMART)

Asthma

Colombia
AstraZeneca

Completed

Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France

Breast Cancer
AstraZeneca

Completed

Parameters of Acceptability, Compliance and Efficacy of Fulvestrant in Post-menopausal Patients With Advance Breast Cancer (FRAME)

Breast Cancer

Argentina
AstraZeneca

Completed

Observation of Change in Clinical Global Impression Scores in Schizophrenia Patients Receiving Seroquel XR Treatment

Schizophrenia

Latvia
AstraZeneca

Completed

National Survey on Infiltrative Breast Cancer (CSI)

Infiltrative Breast Cancer

France
AstraZeneca

Completed

Validity of the Spanish Version of Subjective Well-being Under Neuroleptics Scale (SWN-K) in Patients With Schizophrenia (SWN-K)

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorder

Spain
AstraZeneca

Completed

Structured Treatment of Gastroesophageal Reflux in a Company Health Care Setting, -Effect on Quality of Life, Symptoms and Productivity

GERD

Sweden
AstraZeneca

Completed

To Assess Adherence to the Treatment and Quality of Life in Patients With Hypertension (ADHERENCE)

Hypertension

Argentina
AstraZeneca

Completed

Gastroesophageal Reflux Disease (GERD) Segmentation: Document How Swiss General Practitioners (GPs) Allocate Their GERD Patients to the Three GERD Patient Segments

GERD

Switzerland
AstraZeneca

Completed

Adherence to Gastro-protection in Non-steroidal Anti-inflammatory Drug (NSAID) Using Patients (GADES)

Risk Factors | Compliance | Gastroprotector Therapy

Spain
AstraZeneca

Completed

Investigation Into the Correlation of Plasma Hs-CRP Concentrations and Cardiovascular Risk in Korean Population (CALLISTO)

hsCRP

Korea, Republic of
AstraZeneca

Completed

Asthma Control Among Patients Receiving Inhaled Corticosteroids in Thailand

Asthma

Thailand
AstraZeneca

Completed

Patient's Perception in Symptoms Related to Morning Activity Based on Chronic Obstructive Lung Disease (SYMBOL)

COPD

Korea, Republic of
AstraZeneca

Completed

Retrospective Survey for Patients With Hypertension and Diabetes Mellitus (CRYSTAL)

Hypertension

Korea, Republic of
AstraZeneca

Completed

Crestor RUSH (The Efficacy of RosUvaStatin for Korean Dyslipidemia Patients With Hypertension ) (RUSH)

Hypertension | Dyslipidemia

Korea, Republic of
AstraZeneca

Completed

A Descriptive Study to Explore Certain Characteristics of Patients at Risk for Chronic Obstructive Pulmonary Disease (COPD) in a Primary Care Setting

Chronic Obstructive Pulmonary Disease

Sweden
AstraZeneca

Completed

Management of Cardiovascular Risk Factors

Cardiovascular Diseases | Cardiovascular Risk Factors

Switzerland
AstraZeneca
Bristol-Myers Squibb

Terminated

Evaluation of Diabetes Care at Austrian GPs (DCA09)

Type 2 Diabetes
AstraZeneca

Completed

Epidemiological Study to Describe NSCLC Clinical Management Patterns in Europe. Lung-EPICLIN (EPICLIN)

NSCLC

France, Italy, Spain, Turkey, Belgium, Portugal, Greece, Germany
AstraZeneca

Completed

Prevalence of Gastroesophageal Reflux Disease in Primary Care Patients With Upper Gastrointestinal Symptoms

Gastroesophageal Reflux Disease

Bulgaria

3

Subscribe